Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.

Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA

Open source

DOI: 10.1001/jamaoncol.2022.5228
Published: 2023 Jan 1
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2022.5228,
  title = {Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.},
  author = {Yap TA and Bardia A and Dvorkin M and Galsky MD and Beck JT and Wise DR and Karyakin O and Rubovszky G and Kislov N and Rohrberg K and Joy AA and Telli ML and Schram AM and Conte U and Chappey C and Stewart R and Stypinski D and Michelon E and Cesari R and Konstantinopoulos PA},
  year = {2023},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2022.5228},
  url = {https://doi.org/10.1001/jamaoncol.2022.5228}
}

RIS

TY  - JOUR
TI  - Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
AU  - Yap TA
AU  - Bardia A
AU  - Dvorkin M
AU  - Galsky MD
AU  - Beck JT
AU  - Wise DR
AU  - Karyakin O
AU  - Rubovszky G
AU  - Kislov N
AU  - Rohrberg K
AU  - Joy AA
AU  - Telli ML
AU  - Schram AM
AU  - Conte U
AU  - Chappey C
AU  - Stewart R
AU  - Stypinski D
AU  - Michelon E
AU  - Cesari R
AU  - Konstantinopoulos PA
PY  - 2023
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2022.5228
UR  - https://doi.org/10.1001/jamaoncol.2022.5228
ER  -

APA

TA, Y., A, B., M, D., MD, G., JT, B., DR, W., O, K., G, R., N, K., K, R., AA, J., ML, T., AM, S., U, C., C, C., R, S., D, S., E, M., R, C., & PA, K. (2023). Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2022.5228

Source records

pubmed · retrieved 2026-09-26T09:20:20.772Z
europe-pmc · retrieved 2026-09-26T09:20:20.794Z